EN DE
Watch Verastem Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Verastem Inc (VSTM) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Verastem Inc stock $5.08, price $8.73, that is 41.8% below the price, quality 22 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

VI Verastem Inc logo Thin data Nov 11, 2026

Verastem Inc

VSTM · US
Very expensive, weak quality

Our calculation puts a fair price 42% below what the stock costs today.

Revenue last quarter +114% vs. a year ago.
Moderate debt
Insiders sold $498,284 (6M)
Fair value $5.08 · Strongly overvalued
Quality 22/100
Weak Growth (revenue 5y −19.0 %/yr in USD)
Loss-making · -178.4% net margin (TTM)
Negative free cash flow
Trails peers (1/9)
Narrow moat 4/100 · thin data
Thin data
Estimate
Watch Verastem Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$38.52 $2.20 Fair Value $5.08 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $2.20 – $38.52 · fair‑value band $3.81 – $6.35 · the $8.73 price screens above the $5.08 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Verastem in your weekly email

Every Wednesday you see whether Verastem is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.

Show moreShow less

Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.

The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205.

It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans.

In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets.

The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Stock analysis

Verastem Inc (VSTM) currently trades at $8.73, while our estimate is $5.08, 42% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $3.81 (bear) to $6.35 (bull), the price of $8.73 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Verastem Inc reported revenue of $30.9M in FY2025 versus $2.1M in FY2021, a compound +97.0%/yr. Reported net income was −$209M in FY2025.

Key figures

Market cap $1.1B Small · P/S ratio 10.9 · EPS (TTM) $−1.84 · Return on equity −471% · Return on assets (EBIT) −75.4% (5-year average) · Operating margin −313% · Revenue growth (YoY) +114% · Free cash flow −$138M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 4 out of 100 (low confidence).

What moves the price

The share trades about 18% below its 52-week high and 153% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −42%, VSTM screens richer than that median.

Fair Value

Bear $3.81 Fair Value $5.08 Bull $6.35
Price $8.73 · Downside -41.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 22/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 73
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 37
Debt, balance sheet and risk of trouble
Investment 23
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 73
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 58
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors sold shares worth $498,284 and none bought.

  • SaleDan PatersonPresident and CEO, Director13× since Nov 21, 2025: 108,083 shares, avg. $7.73$835,414Nov 3, 202610b5-1 plan
  • SaleDaniel CalkinsChief Financial Officer5× since Dec 24, 2025: 11,829 shares, avg. $6.32$74,749Oct 1, 202610b5-1 plan
  • SaleRobert E. GagnonDirector283 shares at $9.14$2,587Dec 16, 202510b5-1 plan
  • SaleBrian M StuglikDirector592 shares at $9.14$5,411Dec 16, 202510b5-1 plan
  • SaleMichael KauffmanDirector8,550 shares at $10.00$85,500Nov 21, 202510b5-1 plan
  • SalePaul A. BunnDirector6,250 shares at $10.00$62,500Nov 21, 202510b5-1 plan

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+209.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+128.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.0%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−55.8% (2020) → −550.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

VSTM screens overvalued: fair value 42% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Verastem Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 22 · Bottom 25%
Fair Value upside −41.8% · Below median
Profitability
Return on assets −85.0% · Bottom 25%
Net margin (12 months) −178.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 113.6% · Top 25%
Balance sheet
Debt / equity 1.42× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 19.17× · Priciest 25%
P/S (12 months) 10.93× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)29 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs VSTM
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs VSTM
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs VSTM
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs VSTM
argenx SE ARGX $971.55 $908.40 −7% vs VSTM
CSL Limited CSL A$201.68 A$181.40 −10% vs VSTM
Moderna, Inc MRNA $250.83 $158.70 −37% vs VSTM
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs VSTM
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs VSTM
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs VSTM

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Verastem Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Verastem Inc Fair Value". https://www.fairvalue-calculator.com/stock/VSTM

Frequently asked questions

Is Verastem Inc (VSTM) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $5.08 versus a price of $8.73, about 42% lower (overvalued).
What is the fair value of VSTM?
Our estimate for Verastem Inc is $5.08 (as of Nov 11, 2026), built from audited fundamentals. The current price: $8.73.
What is the quality score of VSTM?
Verastem Inc has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Verastem Inc (VSTM)?
Our calculated price target is the estimate of $5.08 (as of Nov 11, 2026). Cautious scenario $3.81, optimistic scenario $6.35. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Verastem Inc stock forecast for 2026?
Our estimate puts fair value at $5.08, about 42% lower versus a price of $8.73 (overvalued). Cautious scenario $3.81, optimistic scenario $6.35. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Verastem Inc (VSTM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Verastem Inc it is $5.08 per share (as of Nov 11, 2026), against a price of $8.73.
Is Verastem Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, VSTM trades above its calculated fair value: price $8.73, fair value $5.08, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VSTM?
No. The price is what the market pays today ($8.73); the fair value is what the company's own numbers justify ($5.08). For Verastem Inc the two are $3.65 per share apart. That gap is exactly why we show both numbers side by side.
How much is Verastem Inc worth?
The market values Verastem Inc at about $1.1B (market capitalisation, as of Nov 11, 2026). Per share that is $8.73; our models calculate a fair value of $5.08 per share.
What do the bullish and bearish scenarios say about VSTM?
Our models span a range for Verastem Inc: cautious scenario $3.81, base $5.08, optimistic $6.35 per share (as of Nov 11, 2026, price $8.73). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Verastem Inc (VSTM)?
Balance-sheet figures for Verastem Inc (as of Nov 11, 2026): return on equity −471.2%, debt of 1.42 per unit of equity. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is VSTM from its 52-week high?
Verastem Inc trades at $8.73, about 18% below its 52-week high of $10.64 and 153% above the low of $3.45 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $5.08 is for.
Which stocks are comparable to Verastem Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Verastem Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $8.73, calculated fair value $5.08 (−42%), Quality Score 22/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Verastem Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Verastem Inc (VSTM)?
The closing price on Nov 10, 2026 was $8.73. Our estimate is $5.08, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Verastem Inc right now?
The price sits above even our optimistic bull case ($6.35). The favourable scenario is already priced in. Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Verastem Inc

How large is the market capitalisation of Verastem Inc (VSTM)?
The market capitalisation of Verastem Inc is $1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Verastem Inc (VSTM)?
The price-to-sales ratio of Verastem Inc is 10.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Verastem Inc (VSTM)?
Earnings per share at Verastem Inc are $−1.84. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Verastem Inc (VSTM)?
The return on equity (ROE) of Verastem Inc is −471% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Verastem Inc (VSTM)?
On an EBIT basis the return on assets of Verastem Inc is −75.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Verastem Inc (VSTM)?
The operating margin of Verastem Inc is −313% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Verastem Inc (VSTM)?
Revenue at Verastem Inc is growing +114% versus a year earlier (3y avg +128%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Verastem Inc (VSTM) generate?
The free cash flow of Verastem Inc is −$138M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Verastem Inc (VSTM) hold?
Verastem Inc holds more cash than debt, $128M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Verastem Inc in the live analysis

One click puts Verastem Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.